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Abstract. This study was designed to evaluate the accuracy of ultrasonog-
raphy alone and in combination with fine-needle aspiration biopsy
(FNAB) for detection of axillary metastases of nonpalpable lymph nodes
in breast cancer patients. Ultrasonography was carried out in 150 axillas
of 148 patients (mean age 57 years, range 30–80 years); and in 93 axillas
lymph nodes were detected. Nodes were described according to their
dimension and echo patterns and were compared with histopathologic
results. FNAB was carried out in 81 axillas (122 nodes). The sensitivity of
ultrasonography was highest (87%) when size (length >5 mm) was used
as criterion for malignancy, but the specificity was rather low (56%).
When nodes with a malignant pattern (echo-poor or inhomogeneous)
were visualized, specificity was 95%. Ultrasound-guided FNAB had a
sensitivity of 80% and a specificity of 100% and detected metastases in
63% of node-positive patients. It is concluded that FNAB is an easy,
reliable, inexpensive method for identifying patients with positive nodes.
In the case of negative findings, other diagnostic procedures to exclude
lymph node metastases, such as sentinel node mapping, could be per-
formed.
In breast cancer patients the number and level of axillary lymph
node metastases are important prognostic indicators and deter-
minants for selecting patients who should receive adjuvant treat-
ment [1]. Complete axillary dissection with histologic examination
of nodes provides the most accurate information about nodal
status [2–4]. However, node-negative patients who are not se-
lected for adjuvant treatment probably do not benefit by this
procedure, which causes morbidity [5] and prolongs hospital stay
[6]. Efforts have been made to avoid complete axillary dissection
by preoperative evaluation with imaging techniques [7] or intra-
operative assessment by axillary node sampling [8].
Ultrasonography has been used as an imaging method to detect
axillary nodes of breast cancer patients in several studies [9–13].
Patients with and without clinically positive nodes were included
in these studies, and ultrasonographic enlargement of a node
was used as the only criterion for malignancy. The results may
differ for patients with clinically negative nodes, and nodal size
alone is reported to be of limited value for ultrasonographic
differentiation between benign and malignant disease [14]. Better
results can be obtained with high resolution ultrasonography using
ultrasonomorphologic features as criteria for malignancy [14].
Combining ultrasonography with fine-needle aspiration biopsy
(FNAB) may further improve the presurgical staging of the axilla
in breast cancer patients [15].
The purpose of this prospective study was to assess the accuracy
of ultrasonography (using ultrasonomorphologic criteria for ma-
lignancy) and of ultrasound-guided FNAB for detection of axillary
lymph node metastases in breast cancer patients without palpable
nodes at clinical examination.
Methods
During a 15-month period all patients with proved breast cancer
without palpable axillary nodes and amenable to axillary dissec-
tion were included in the study. The absence of clinically enlarged
nodes was confirmed by two experienced clinicians. Excluded
were patients who underwent preoperative radiotherapy or che-
motherapy. The day before surgery ultrasound examination of the
ipsilateral axilla was carried out by two experienced radiologists
using a 7.5 MHz linear array transducer (Acuson 128). The area
between the axillary vein, latissimus dorsi muscle, and medial
border of the pectoralis minor muscle was carefully inspected.
Any definable mass within the axilla was considered to be a lymph
node.
The echo patterns of axillas without visible nodes and axillas
with nodes with an echo-rich or homogeneous aspect, so called
benign characteristics [14, 16], were considered not suspect forCorrespondence to: A.N. van Geel, M.D., Ph.D.
malignancy. Echo-poor and inhomogeneous nodes were consid-
ered suspect for metastatic deposit [14, 16]. The length of the
node, defined as the largest diameter on ultrasonography (US) in
millimeters, was scored. An ultrasound-guided FNAB was ob-
tained with a 21-gauge needle from at least one visible node,
regardless of the echo pattern, with a maximum of four biopsies
per axilla. The aspirated node was marked by leaving 0.5 cm of a
guidewire to make a comparison with histologic findings possible.
The aspiration biopsies were analyzed for cytologic features and
classified as benign or malignant. After FNAB all patients under-
went complete axillary dissection and resection of the primary
tumor either by segmental or total mastectomy. The standard
anatomic borders of the axillary dissection were the axillary vein,
latissimus dorsi muscle, medial border of the pectoralis minor
muscle, serratus anterior muscle, and subscapular muscle. Level I,
II, and III nodes were resected. The specimen was examined by
radiology and the marked nodes were indicated with needles for
easy localization by the pathologist. All axillary specimens were
processed for histologic examination using hematoxylin and eosin
(H&E) and examined by the pathologist.
The results were analyzed with descriptive statistical methods.
Sensitivity, specificity, overall accuracy, and positive and negative
predictive values were calculated by comparing the results of







Sensitivity: A/A1 C; specificity: D/D1 B; overall accuracy: A1D/A
1 B 1 C 1 D; positive predictive value: A/A 1 B; negative predictive
value: D/D 1 C.
Results
Ultrasonography was performed in 150 axillas of 148 patients.
Two patients with synchronous bilateral breast cancer underwent
bilateral examination and axillary dissection. The age range was
30 to 80 years (mean 57 years). The histology of the primary
tumor was invasive ductal carcinoma in 135 patients (91%),
invasive lobular carcinoma in 6 patients (4%), and other histologic
types of breast cancer in 7 patients. There were 78 T1 tumors
(51%), 66 T2 tumors (43%), and 6 T3 tumors (6%). The mean
number of nodes in the axillary specimen was 14 (range 4–32).
Lymph node metastases were present in 62 axillas (41%), 40 of
these having fewer than four positive nodes (26 axillas one node,
7 two nodes, 7 three nodes), 22 axillas having four or more
positive nodes. The ultrasound examination detected axillary
nodes in 93 axillas (62%); no nodes could be detected in 57 axillas
(38%). A total of 143 nodes could be visualized, of which 122 were
aspirated. In 47 axillas one, in 29 axillas two, in 3 axillas three, and
in 2 axillas four successful biopsies were performed. In 12 axillas
with 21 visualized nodes FNAB was not possible because the
position of the node was too difficult, the node was too small, or
no adequate material could be obtained. The mean length of the
nodes was 14 mm (range 6–25 mm).
The results of ultrasonography, cytology, and histology of the
lymph nodes are summarized in Table 1. The aspects of the lymph
nodes detected by ultrasonography were categorized as not sus-
pect for malignancy, suspect for malignancy, or no classification
possible, as described above, and compared with the gold stan-
dard: the results of the histologic examination. The sensitivity was
36%, specificity 95%, overall accuracy 67%, positive predictive
value 86%, and negative predictive value 63% (Table 2).
In previous studies all axillary nodes visualized with ultrasonog-
raphy [10–12] or nodes with a diameter of at least 5 mm [9] were
considered as involved with metastasis. The diameter of the
smallest node detected in our study was 6 mm. When any visible
node was defined as malignant, sensitivity was 87%, specificity
56%, overall accuracy 68%, and positive and negative predictive
values 58% and 86%, respectively (Table 2).
The results of FNAB versus histologic outcome are summarized
in Figure 1. Positive cytologic analysis (one or more nodes
positive) was found in 39 axillas. All the positive cytologies were
confirmed to be metastatic by light microscopic examination. Of
the cytologic negative axillas, 10 of 42 (24%) were positive for
malignancy with histologic examination. The number of positive
nodes per axilla clearly influenced the chance of detection: only 11
of 26 axillas with one positive node were detected by FNAB, in
contrast to 19 of 22 axillas with four or more positive nodes. It was
possible to detect 39 (63%) of the 62 positive axillas in 26% of the
total patient population. The sensitivity of FNAB was 80%, the
specificity 100%, the overall accuracy 88%, and the positive and
negative predictive values 100% and 76%, respectively (Table 2).
Discussion
Axillary dissection has a central place in breast cancer treatment,
although debate exists about the extent of dissection necessary for
adequate staging [17]. Complete axillary dissection can be consid-
ered overtreatment for those patients whose nodes do not contain













Target 9 39 10 58 25
Homogeneous 2 10 18 30 21
Malignant
Hypoechogenic 7 6 16 29 25
Inhomogeneous 0 3 4 7 6
No classification 3 7 9 19 14
Total 21 65 57 143 91









Sensitivity 36 87 80
Specificity 95 56 100
Overall accuracy 67 68 88
Positive predictive value 86 58 100
Negative predictive value 63 86 76
Bonnema et al.: Aspiration of Axillary Nodes 271
metastases with histologic examination [18]. Most of these pa-
tients have T1 and T2 tumors, as it is well established that the
incidence of lymph node involvement increases with increasing
diameter of the tumor [19]. This correlation is already seen for
small (T1) tumors [18]. In our study T1 and T2 tumors were found
in 94% of the patients, and lymph node metastases were present
in 41%. As the number of patients presenting with early stage
breast cancer without axillary metastases will increase as a result
of breast screening activities, the need to look for alternatives for
axillary dissection becomes more compelling [20]. The use of
neoadjuvant chemotherapy necessitates alternative techniques for
assessment of metastatic status of axillary nodes [21]: first to select
patients with positive nodes and second because of a lack of
histopathologic control of treatment results during chemotherapy.
Clinical examination for assessment of axillary metastases is
notoriously unreliable, with an overall error rate of 39% and a
false-negative rate up to 45% [22]. No imaging technique until
now has been successful enough to replace the histologic exami-
nation. One should realize that it will be almost impossible to
reach a sensitivity higher than 90% with any imaging technique
because occult micrometastases are found in at least 9% of
patients [23]. The results of radionuclide lymphography [24] or
immunoscintigraphy [25] do not differ from those of the clinical
examination. CT scans and MRI are limited to diagnosing en-
largement of lymph nodes without being able to differentiate
between those infiltrated with cancer from hyperplastic glands [26,
27]. Other drawbacks of CT and MRI are the high cost and the
difficulty of obtaining material for pathologic analysis. New tech-
niques such as positron emission tomography are even costlier
than CT and MRI, and experiences with this method are limited
[28]. Ultrasonography, a frequently used technique for lymph
node imaging, is characterized by low cost and the possibility of
obtaining biopsy specimens. Several studies have shown that
ultrasonography has value for the detection of enlarged lymph
nodes in breast cancer [9–13], head and neck cancer [29–31], and
gastrointestinal cancer [32]. For the detection of axillary node
metastases in breast cancer the sensitivity and the specificity
varied between 56% and 72% and 70% and 90%, respectively
[9–13]. A problem is, as in the case of CT and MRI, the
differentiation between benign and malignant nodes. Nodal size
has been tested for validity as a criterion for malignancy. For
cervical nodes the minimal axial diameter (2–30 mm) was the
most accurate parameter to use for predicting tumor-positive
nodes [31]. Nodal size varies among the regions in the body, and
size criteria for malignancy of lymph nodes in the axilla are not
known. We detected nodes only with a longitudinal diameter of 6
mm or more. If enlargement was used as the only criterion for
malignancy, the sensitivity of ultrasonography was 87% and the
specificity only 56%.
High-resolution ultrasonography enables differentiation be-
tween benign and malignant echo pattern characteristics [14].
Nodes with an echo-rich center are expected to be benign, and
nodes with an echo-poor center or inhomogeneous architecture
are more suspect for tumor infiltration [14, 16, 33]. We used this
technique in our study. Sensitivity was low (36%) and specificity
high (95%), which means that ultrasonography of axillary nodes is
more accurate for the diagnosis of metastatic than nonmetastatic
lymph nodes. However, the accuracy of ultrasonography is too low
to rely on this technique for selection of node-negative or
node-positive patients. Therefore we combined ultrasonography
with FNAB of visualized nodes. The latter is a reliable method for
diagnosing primary carcinoma of the breast [34]. In our study,
FNAB could not improve the sensitivity of ultrasonography alone,
because of a false-negative rate of 12%. Analysis of the false-
negative findings showed that 7 of the 10 false-negative axillas
contained only one metastatic node, which makes it more difficult
to aspirate the right node. Ultrasound-guided FNAB therefore
cannot be used to select patients with negative nodes in whom an
axillary dissection can be omitted for this reason. The specificity of
the technique, however, was 100%, as there were no cases of
positive cytology that proved to be negative on histology. In our
study population of 148 patients with 62 node positive axillas, 39
of these patients (63%) could be accurately detected by ultra-
sound-guided FNAB. The high specificity makes the technique
valuable for staging patients entering neoadjuvant chemotherapy
protocols and others who are not selected for surgery as primary
treatment.
Experiments with sentinel node resection have also successfully
identified node-positive breast cancer patients [35, 36]. Although
the technique is more conservative than axillary dissection, surgi-
cal resection of the sentinel node with some form of anesthesia is
still needed. Ultrasound-guided FNAB is minimally invasive,
needs no anesthesia, and is easier to perform than the sentinel
node biopsy. It can detect 63% of positive axillas in patients with
small breast tumors. In our opinion, the sequence of diagnostic
procedures in the future to detect axillary node metastases could
be to perform first FNAB and, in case of negative findings, a
sentinel node biopsy. The technical ease of the procedures and the
major reduction in morbidity and costs that can be expected justify
larger clinical trials to verify the feasibility and accuracy of these
new diagnostic methods.
In conclusion, ultrasound-guided FNAB has a high sensitivity
and specificity for detecting axillary lymph node metastases in
patients with T1 and T2 tumors. In this study 63% of node-
positive patients could be identified as having metastases. In these
patients other, more invasive diagnostic methods can be avoided.
Fig. 1. FNAB and cytologic and histologic results. n 5 number of axillas;
cyt2: cytologic outcome benign; cyt1: cytologic outcome malignant;
hist2: histologic outcome benign; hist1: histologic outcome malignant.
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Re´sume´
Le but de cette e´tude a e´te´ d’e´valuer la pre´cision de l’e´chographie
seule ou associe´e a` la ponction biopsique a` l’aiguille (PBA) pour
de´tecter des me´tastases axillaires des ganglions lymphatiques
non-palpables chez la femme ayant un cancer du sein. On a
examine´ en e´chographie 150 aisselles chez 148 femmes (aˆge
moyen 57 ans; extreˆmes 30–80 ans); on a ainsi de´tecte´ 93
ganglions. Les ganglions ont e´te´ analyse´s selon leur dimensions et
leur caracte`res e´choge´niques et ces re´sultats ont e´te´ compare´s aux
donne´es de l’examen anatomopathologique. Cent vingt-deux gan-
glions ont fait l’objet de PBA (81 creux axillaires). La sensibilite´
de l’e´chographie a e´te´ la meilleure (87%) lorsque l’on a pris la
taille (.5 mm) comme crite`re de malignite´, alors que pour ce
meˆme crite`re, la spe´cificite´ a e´te´ relativement basse (56%). En
prenant comme crite`re les caracte`res e´choge´niques (visualisation
difficile ou he´te´roge`ne), la spe´cificite´ a e´te´ de 95%. La PBA
e´choguide´e avait une sensibilite´ de 80% et une spe´cificite´ de
100%; elle a de´tecte´ des me´tastases chez 63% des patientes ayant
des ganglions positifs. On conclue que la PBA est une me´thode
facile, fide`le et peu couˆteuse pour identifier les patients ayant des
ganglions positifs. En cas d’examen ne´gatif, on pourrait alors
envisager d’autres investigations telles que la cartographie des
ade´nopathies sentinelles.
Resumen
El presente estudio fue disen˜ado para evaluar la precisio´n de la
ultrasonografı´a sola o en combinacio´n con aspiracio´n con aguja
fina (AAF) en la deteccio´n de meta´stasis axilares en ganglios
linfa´ticos no palpables en pacientes con ca´ncer mamario. Se
practico´ ultrasonografı´a en 150 axilas de 148 pacientes (edad
promedio de 57 an˜os, rango 30–80 an˜os) y en 93 axilas se
detectaron ganglios. Los ganglios fueron descritos de acuerdo con
su dimensio´n y patro´n ecoge´nico, para comparacio´n con los
resultados histopatolo´gicos. En 81 axilas (122 ganglios) se practico´
AAF. La sensibilidad de la ultrasonografı´a fue ma´xima (87%)
cuando el taman˜o (longitud .5 mm) fue utilizado como criterio
de malignidad, pero la especificidad fue ma´s bien baja (56%).
Cuando se visualizaron ganglios con patro´n de malignidad (eco-
genicidad pobre o poca homogeneidad), la especificidad fue 95%.
La AAF guiada por ultrasonografı´a tuvo una sensibilidad de 80%
y una especificidad de 100% y detecto´ meta´stasis en 63% de las
pacientes con ganglios positivos. Se concluye que la AAF es un
me´todo fa´cil, confiable y de bajo costo para identificar pacientes
con ganglios positivos. En el caso de hallazgos negativos, se
pueden practicar otros procedimientos diagno´sticos para excluir
meta´stasis ganglionares, tales como mapeo de ganglios centinela.
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Invited Commentary
Alastair R. Brown, M.D.
Royal North Shore Hospital, Sydney, Australia
This report by Bonnema et al. describes a well conducted study
that has demonstrated that the addition of FNAB to the use of
ultrasound for examining axillary lymph nodes in breast cancer
patients can significantly enhance the specificity of the examina-
tion. Although it also improves the sensitivity, there is unfortu-
nately a significant margin of error in relation to the negative
results. Of the 150 axillas examined, 39 were positive by this
technique, and all were confirmed to be histologically positive.
However, a further 23 axillas were also found to be histologically
positive, but of these 8 had no visible nodes on ultrasound scans
and 5 were not able to have FNAB done; the other 10 had FNAB
done, but the cytology was negative.
In current practice, axillary lymph node dissection has a diag-
nostic as well as a therapeutic function. The diagnosis of axillary
lymph node involvement is the most important prognostic indica-
tor in breast cancer, and an adequate axillary dissection, as part of
the primary treatment, is considered by many authorities to confer
a positive therapeutic advantage in patients with involved nodes.
However, axillary dissection is associated with significant long-
term, as well as short-term, morbidity. Such morbidity is always
undesirable, but it is even less tolerable for patients whose nodes
prove to be clear. If therefore a reliable noninvasive diagnostic
technique could be developed for identifying the patients who
need a therapeutic axillary dissection and those who do not (i.e.,
which patients have involved nodes and which do not) without
having to perform a diagnostic axillary dissection, it would have
the potential for widespread application. Unfortunately, with its
present level of sensitivity, this technique cannot yet fill that role.
If neoadjuvant systemic therapy, hormonal or chemotherapeu-
tic, were to be given to all patients regardless of their lymph node
status, it could be argued from the point of view of locoregional
control that axillary dissection could be deferred, and blind
adjuvant radiotherapy to the axilla also withheld until such time as
involvement of the nodes was confirmed—as is usually done with
skin malignancies. Under such circumstances the use of US with
FNAB would be a useful part of such imaging surveillance.
However, at the present time few clinicians (or patients) are able
to accept a “wait and see” plan of management for the axilla in the
presence of invasive cancer of the breast. It would require a
controlled clinical trial, therefore, to determine whether such a
plan of management could be recommended.
For the present, the technique seems to have a limited diag-
nostic role, because it cannot yet be relied on for making such
important therapeutic decisions as whether to dissect the axilla.
Nevertheless, it is a technique worth developing, and we look
forward to reading more reports of experience with its use and, it
is hoped, a controlled clinical trial of its application in a thera-
peutic setting.
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